News | November 12, 2021
Covaxin well tolerated with no safety concerns: Lancet
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
The injunction order has been passed against Natco Pharma, Torrent Pharmaceuticals, Eris Lifesciences and Windlas Biotech
Expertise in exosomes isolation and characterization will drive innovation in this field
This approval of shelf-life extension was based on the availability of additional stability data, which was submitted to CDSCO
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
Subscribe To Our Newsletter & Stay Updated
